Study of MeRes100 in the Treatment of Patient With Coronary Artery Disease.

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 484 participants.

Also called NCT03454724

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 484 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03454724
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03454724. Randomized; no masking; primary purpose treatment. Start 2020-01-01 (anticipated); primary completion 2020-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of MeRes100 in the Treatment of Patient With Coronary Artery Disease.
Acronym
MeReS100-China
Intervention (Device)
MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System
Intervention (Device)
Xience EES Everolimus Eluting Coronary Stent System
Lead sponsor
Meril Life Sciences Pvt. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03454724
Content hash
57d37e1c9630f7b031f7856e61b3716a28287f4d251a36fd143adc73d1a2e903